Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing innovative gene therapies for patients suffering from rare and devastating monogenic diseases, with a particular focus on the central nervous system. The company leverages its proprietary adeno-associated virus (AAV) gene therapy platform to create transformative treatments for conditions with significant unmet medical needs. Taysha's robust pipeline includes multiple product candidates targeting a range of severe genetic disorders, such as giant axonal neuropathy, Rett syndrome, CLN7 disease, CLN1 disease, SLC13A5 deficiency, tauopathies, Angelman syndrome, fragile X syndrome, and GM2 gangliosidosis. This broad portfolio reflects a strategic approach to addressing diverse genetic targets and patient populations within the rare disease space. The company's business model is centered on advancing these novel therapies through clinical development and ultimately to commercialization, aiming to provide life-changing options for patients and their families. Taysha's scientific foundation is strengthened by a key research and collaboration agreement with The University of Texas Southwestern Medical Center, providing access to cutting-edge research and expertise. By focusing on the development of AAV-based gene therapies for debilitating neurological conditions, Taysha Gene Therapies positions itself as a significant player in the rapidly evolving field of genetic medicine, striving to bring hope and effective treatments to those with limited therapeutic alternatives.